肝炎病毒相关性肝细胞癌的抗病毒治疗现状与挑战

董菁; 江家骥

doi:10.3969/j.issn.1001-5256.2017.07.013

肝炎病毒相关性肝细胞癌的抗病毒治疗现状与挑战

DOI: 10.3969/j.issn.1001-5256.2017.07.013

董菁,
江家骥

福建医科大学附属第一医院肝病中心

详细信息

中图分类号: R512.6;R735.7
计量
- 文章访问数: 2273
- HTML全文浏览量: 11
- PDF下载量: 487
- 被引次数: 0
出版历程
- 收稿日期: 2017-04-09
- 出版日期: 2017-07-20

Antiviral therapy for hepatitis virus-related hepatocellular carcinoma:current status and challenges

Liver Diseases Research Center, The First Affiliated Hospital of Fujian Medical University

摘要

摘要: 全球肝细胞癌（HCC）发生率在上升,东亚和我国部分地区呈下降趋势,但在我国仍属于发病率和病死率靠前的疾病。研究提示抗病毒治疗如能长期将HBV复制抑制至极低水平或使HCV感染者获得持续性病毒学应答,则可以降低病毒相关性HCC的发生率。新证据提示PEG-IFNα较核苷类药物和（或）核苷酸类药物具有更好的二级预防作用;IFN类在病毒相关性HCC的三级预防中扮演重要作用。回顾了近两年病毒相关性HCC的流行病学研究和抗病毒治疗在二级/三级预防中的作用,指出充分有效抗病毒治疗是防止HCC发生、复发的基础。
- 癌,肝细胞 /
- 肝炎病毒 /
- 抗病毒药 /
- 治疗
Abstract: The incidence rate of hepatocellular carcinoma (HCC) is increasing around the world and tends to decrease in East Asia and several regions in China;however, China still has higher incidence rate and mortality rate of HCC than most countries.Studies have shown that long-term antiviral therapy can inhibit HBV replication to a very low level or help patients with HCV infection achieve sustained virologic response, which can further reduce the incidence rate of virus-related HCC.New evidence suggests that compared with nucleos (t) ide analogues, PEG-IFNα has a better effect of secondary prevention.Studies also indicate that interferons play an important role in tertiary prevention of virus-related HCC.This article reviews the epidemiological studies on virus-related HCC in recent years and the role of antiviral therapy in second and tertiary prevention and points out that adequate and effective antiviral therapy is the basis for preventing the development and recurrence of HCC.
- carcinoma, hepatocellular /
- hepatitis viruses /
- antiviral agents /
- therapy

HTML全文

参考文献(19)

[1]Liver Cancer Study Group, Chinese Society of Hepatology, Chinese Medical Association.Recommendation on antiviral therapy to hepatitis B/C virus related hepatocellular carcinoma[J].J Clin Hepatol, 2013, 29 (1) :5-9. (in Chinese) 中华医学会肝病学分会肝癌学组.HBV/HCV相关性肝细胞癌抗病毒治疗专家建议[J].临床肝胆病杂志, 2013, 29 (1) :5-9.

[2]Expert Panel of Antiviral Therapy for Hepatocellular Carcinoma.Expert consensus on antiviral therapy to hepatitis B/C virus-related hepatocellular carcinoma[J].J Clin Hepatol, 2014, 30 (5) :390-395. (in Chinese) 肝细胞癌抗病毒治疗专家组.HBV/HCV相关性肝细胞癌抗病毒治疗专家共识[J].临床肝胆病杂志, 2014, 30 (5) :390-395.

[3]DONG J, JIANG JJ.Explanation of the“Expert consensus on antiviral therapy to hepatitis B/C virus-related hepatocellular carcinoma”.[J]J Clin Hepatol, 2014, 30 (7) :592-595. (in Chinese) 董菁, 江家骥.《HBV/HCV相关性肝细胞癌抗病毒治疗专家共识》解读[J].临床肝胆病杂志, 2014, 30 (7) :592-595.

[4]STEWART BW, BRAY F, FORMAN D, et al.Cancer prevention as part of precision medicine:‘plenty to be done’[J].Carcinogenesis, 2016, 37 (1) :2-9.

[5]CHEN W, ZHENG R, BAADE PD, et al.Cancer statistics in China, 2015[J].CA Cancer J Clin, 2016, 66 (2) :115-132.

[6]TANG ZY.Studies on liver cancer:evolution and perspectives[J].JClin Hepatol, 2014, 30 (3) :193-196. (in Chinese) 汤钊猷.肝癌研究的变迁与趋势[J].临床肝胆病杂志, 2014, 30 (3) :193-196.

[7]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B:a 2015 update[J].J Clin Hepatol, 2015, 31 (12) :1941-1960. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1941-1960.

[8]LYU X, LIU K, CHEN Y, et al.Analysis of risk factors associated with the development of hepatocellular carcinoma in chronic HBV-infected Chinese:a meta-analysis[J].Int J Environ Res Public Health, 2016, 13 (6) :e604.

[9]LEE MH, YANG HI, LIU J.Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients:risk scores integrating host and virus profiles[J].Hepatology, 2013, 58 (2) :546-554.

[10]LEE MH, LU SN, YUAN Y, et al.Development and validation of a clinical scoring system for predicting risk of HCC in asymptomatic individuals seropositive for anti-HCV antibodies[J].PLo S One, 2014, 9 (5) :e94760.

[11]BRUCHER BL, JAMALL IS.Epistemology of the origin of cancer:a new paradigm[J].BMC Cancer, 2014, 14:331.

[12]TU T, BUDZINSKA MA, MACZUREK AE, et al.Novel aspects of the liver microenvironment in hepatocellular carcinoma pathogenesis and development[J].Int J Mol Sci, 2014, 15 (6) :9422-9458.

[13]SINN DH, GWAK GY, CHO J, et al.Comparison of clinical manifestations and outcomes between hepatitis B virus-and hepatitis Cvirus-related hepatocellular carcinoma:analysis of a nationwide cohort[J].PLo S One, 2014, 9 (11) :e112184.

[14]LIANG KH, HSU CW, CHANG ML, et al.Peginterferon is superior to nucleos (t) ide analogues for prevention of hepatocellular carcinoma in chronic hepatitis B[J].J Infect Dis, 2016, 213 (6) :966-974.

[15]CHEUNG MC, WALKER AJ, HUDSON BE, et al.Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis[J].J Hepatol, 2016, 65 (4) :741-747.

[16]XU J, LI J, CHEN J, et al.Effect of adjuvant interferon therapy on hepatitis B/C virus-related hepatocellular carcinoma after curative therapy-meta-analysis[J].Adv Clin Exp Med, 2015, 24 (2) :331-340.

[17]KANOGAWA N, OGASAWARA S, CHIBA T, et al.Sustained virologic response achieved after curative treatment of hepatitis C virus-related hepatocellular carcinoma as an independent prognostic factor[J].J Gastroenterol Hepatol, 2015, 30 (7) :1197-1204.

[18]MARCELLIN P, AHN SH, MA X, et al.Combination of tenofovir disoproxil fumarate and peginterferonα-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B[J].Gastroenterology, 2016, 150 (1) :134-144.

[19] SARIN SK, KUMAR M, LAU GK, et al.Asian-Pacific clinica practice guidelines on the management of hepatitis B:a 2015 update[J].Hepatol Int, 2016, 10 (1) :1-98.

施引文献

资源附件(0)

访问统计